BOSTON (GenomeWeb News) — Oxford Gene Technology has closed one of its business units as it concentrates on developing and launching new microarray products and growing its licensing revenue in newer markets like Japan, according to a company official.
OGT's CEO Mike Evans said this week that OGT had decided to close down the unit, called Tridend, because it "didn't fit with OGT's core strategy." Evans spoke with GenomeWeb News at IBC Life Sciences' Discovery 2 Diagnostics conference, held here this week.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.